Yanina Natanzon
Yanina Natanzon publishes mostly in Pulmonary and Respiratory Medicine, Oncology and Cancer Research, on topics such as Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics and Economic and Financial Impacts of Cancer.
- World rank
- #1,572,219 of 7,710,434 ranked researchers
- Rank in United States
- #490,073 of 1,627,098
- Works
- 38
- Citations
- 990
- Citations per work
- 26.1
What does Yanina Natanzon research?
Yanina Natanzon's work is mostly in Medicine (27%), Biochemistry, Genetics and Molecular Biology (22%), Economics, Econometrics and Finance (10%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Everything else1334.0%
- Health Sciences1027.0%
- Medicine1027.0%
- Life Sciences822.0%
- Social Sciences410.0%
- Physical Sciences37.0%
- Mathematics37.0%
- 1Pulmonary and Respiratory Medicine15% of their works
- 2Oncology12% of their works
- 3Cancer Research11% of their works
- 4Molecular Biology11% of their works
- 5Economics and Econometrics10% of their works
- 6Statistics and Probability7% of their works
Research topics
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Economic and Financial Impacts of Cancer
- Statistical Methods in Clinical Trials
- Cancer Immunotherapy and Biomarkers
- Health Systems, Economic Evaluations, Quality of Life
- Cancer-related molecular mechanisms research
- Epigenetics and DNA Methylation
Which keywords describe Yanina Natanzon's research?
The keywords of their largest research topics: Targeted Therapy, ALK Inhibitors, EGFR Mutations, Cancer Genomics, Cost of Care, Financial Toxicity, Mutational Signatures and Adaptive Designs.
- Histone Modification
- Cancer
- Cost-effectiveness Analysis
- Immune Checkpoint Blockade
- Adaptive Designs
- Financial Toxicity
- Cancer Genomics
- ALK Inhibitors
- Targeted Therapy
- EGFR Mutations
- Cost of Care
- Mutational Signatures
- False Discovery Rate
- PD-1 and PD-L1
- Quality of Life
- DNA Methylation
- Long Noncoding RNAs
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 17 words, with their numbers
- Targeted Therapy162 topics
- ALK Inhibitors101 topic
- EGFR Mutations101 topic
- Cancer Genomics61 topic
- Cost of Care61 topic
- Financial Toxicity61 topic
- Mutational Signatures61 topic
- Adaptive Designs51 topic
- False Discovery Rate51 topic
- Immune Checkpoint Blockade51 topic
- PD-1 and PD-L151 topic
- Cost-effectiveness Analysis41 topic
- Quality of Life41 topic
- Cancer31 topic
- DNA Methylation31 topic
- Histone Modification31 topic
- Long Noncoding RNAs31 topic
Where does Yanina Natanzon work?
Yanina Natanzon's main affiliation in the publication record is Concert Pharmaceuticals (United States), United States.
How many publications and citations does Yanina Natanzon have?
OpenAlex counts 38 works and 990 citations for Yanina Natanzon, an h-index of 11, ranking #1,572,219 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Yanina Natanzon. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.